Dermatology co Foamix mulls Nasdaq IPO
Jose Manuel Barroso's visit will focus on the Agreement on Conformity Assessment and Acceptance of Industrial Products (ACAA) on pharmaceuticals.
Sources inform ''Globes'' that European Commission President Jose Manuel Barroso will visit Israel, probably on July 8-9. The visit is especially important because Barroso, who has been European Commission President for the past decade, and is one of the most influential men in the organization, is making his first trip to Israel.
Barroso's visit is a major diplomatic coup for Israel, whose relations with the EU hit a new low in mid-May, after the European Council blamed Israel for the diplomatic impasse in the Middle East. Officials in Brussels involved in EU-Israel commercial relations told "Globes" that Barosso's visit will focus on the Agreement on Conformity Assessment and Acceptance of Industrial Products (ACAA) on pharmaceuticals.
Although the ACAA was signed in May 2010, the European Parliament has delayed ratification, for political reasons. "EMPs consider ratification of the agreement as giving Israel a prize, and they don’t want to give it," a top EU official in Brussels told "Globes. Leftist EMPs are behind the non-ratification of the ACAA.
The ACAA will grant reciprocal recognition of Good Manufacturing Practice (GMP) for the manufacture of pharmaceuticals by the authorized agencies in the EU and Israel (the Ministry of Health). The agreement will lift trade barriers and slash drug manufacturing costs, because it will exempt Israeli pharmaceutical manufacturers from the need to carry out additional laboratory tests in Europe, and will allow the Ministry of Health to conduct periodic inspections of GMP and grant permits.
The ACAA will save Israel's pharmaceutical industry hundreds of millions of dollars, boosting an important bilateral trade sector. The ACAA on pharmaceuticals will also set a precedent for other ACAAs for other industries.
"The European Parliament is a purely political body, with no trade or economic considerations. Our connection with the Parliament and EMPs is critical, and we should foster it," Ministry of Industry, Trade and Labor director of bilateral trade relations Etty Levy told "Globes" in an interview in January 2011 to mark the visit by 500 EMPs.
To block the ACAA, EMPs have demanded that it must not apply to laboratories located in the West Bank, and that priority should be given to Palestinian laboratories. Officials in Brussels say that this is impossible, both legally and politically. The ACAA, which has already been signed, explicitly states that it does not relate to origins, and any such change would require rewriting the agreement. "Politically, we understand that [Prime Minister] Benjamin Netanyahu or [Minister of Foreign Affairs] Avigdor Liberman cannot agree to such a change," said one official.
Other Brussels officials involved in the ACAA told "Globes" that there are additional reasons, beside politics, why the European Parliament has delayed ratification. They include the institutional competitiveness that emerged with the coming into effect of the Lisbon Treaty, which gave the European Parliament additional powers. "The Parliament and EMPs are flexing their muscles in order to show the European Commission that reality has changed, and that they have something to say about every issue. That is why they held up the ACAA with Morocco and Colombia, and, most recently, even dumped it with one of the Balkans countries, due to concerns about child labor in the industry."
Published by Globes [online], Israel business news - www.globes-online.com - on June 25, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
The developer of foam-based dermatology treatments is seeking underwriters.
Can-Fite Biopharma raises $5m
The proceeds will finance clinical trials for psoriasis, glaucoma, and liver cancer treatments.
Teva switching Copaxone users to new dosage
"Bloomberg": Teva has switched 8.7% of Copaxone's multiple sclerosis patients to the 40 milligram dosage.
Immune Pharmaceuticals raises $11.7m on Nasdaq
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.